C

Corbus Pharmaceuticals Holdings
D

CRBP

8.83000
USD
-0.36
(-3.92%)
مغلق
حجم التداول
5,394
الربح لكل سهم
-6
العائد الربحي
-
P/E
-2
حجم السوق
108,050,653
أصول ذات صلة
ABBV
ABBV
-1.290
(-0.67%)
191.070 USD
A
ACAD
-0.050
(-0.23%)
21.710 USD
ALNY
ALNY
3.30
(1.08%)
308.00 USD
A
AMRN
-0.080
(-0.60%)
13.250 USD
GILD
GILD
-2.080
(-1.86%)
110.010 USD
I
INVA
0.285
(1.33%)
21.680 USD
NVS
NVS
-1.255
(-1.04%)
119.495 USD
Z
ZYME
-0.430
(-3.28%)
12.670 USD
المزيد
الأخبار المقالات

العنوان: Corbus Pharmaceuticals Holdings

القطاع: Healthcare
الصناعة: Biotechnology
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.